Among the goals of the Department of Health and Human Services and the Food and Drug Administration (FDA) is to improve written communication to patients about their prescription medicines. Bristol-Myers Squibb Company recognizes the need for patients to receive high-quality information regarding their therapeutic options. The company has initiated a program to prepare patient-oriented labeling for certain prescription products for which such material is appropriate, using the FDA’s proposed Medication Guide as a basis for content and format.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Federal Register. 1968;33:8812 (21 CFR 201.305).
Federal Register. 1970;35:9O01 (21 CFR 310.501).
Federal Register. 1977;42:37636 (21 CFR 310.515).
Federal Register. 1978;43:47198 (21 CFR 310.516).
Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information. Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 11.
Federal Register. 1979;44:40016.
Federal Register. 1980;45:60754.
Federal Register. 1981;46:13193.
Federal Register. 1981;46:23739.
Federal Register. 1982;47:39147.
Federal Register. 1995;60:44182.
Federal Register. 1995;60:44199.
Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information. Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 3.
Federal Register. 1998;63:66378-66400.
Jones S, et al. Patient information leaflets for HIV positive patients. Pharmaceut J. Sep 8, 1990;245: 308–309.
Fleckenstein L, et al. Oral contraceptive patient information-a questionnaire study of attitudes, knowledge, and preferred information sources. JAMA. 1976; 235(13):1331–1336.
Smith D. Compliance packaging: a patient education tool. Am Pharmacy. Feb 2, 1989;NS29(2):126–137.
Kuperberg JR, et al. All in one: the user-friendly rx product. Pharmaceut Exec. April 1990:74–78.
Gibbs S, et al. The benefits of prescription information leaflets (1). Br J Clin Pharmacol. 1989;27:723–739.
George CF, et al. Prescription information leaflets: a pilot study in general practice. Brit Med J 1983; 287:1193–1196.
Glazier R, et al. Written patient information about triple-market screening: a randomized, controlled trial. Obstet Gynecol. November 1997;90(5):769–774.
National Institute of Health. Minimizing Medical Product Errors, A Systems Approach, Bethesda, MD; Jan. 8, 1998.
Sless D, Wiseman R. Writing about Medicines for People-Usability Guidelines for Consumer Medicine Information. 2nd ed. Communication Research Institute of Australia. Dickson, Australia. Ch 6, 73-96, Appendices 3, 4, 5, 121-157.
About this article
Cite this article
O’Connell, C.A., Skinner, R. The Patient Labeling Program at Bristol-Myers Squibb. Ther Innov Regul Sci 33, 649–654 (1999). https://doi.org/10.1177/009286159903300301
- Food and Drug Administration
- Patient labeling
- Consumer labeling
- Patient package insert
- Medication Guide
- Healthy People 2000
- Action Plan for the Provision of Useful Prescription Medicine Information